Susceptibility testing: Viral pathogens

Infectious Disease Clinics of North America

Volumn 15, Issue 4, 2001, Pages 1263-1294

  Smith, T F ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACICLOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; FOSCARNET; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ASSAY; CYTOMEGALOVIRUS; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS VIRUS; HERPES SIMPLEX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION SENSITIVITY; NONHUMAN; PHENOTYPE; PHYLOGENY; REVIEW; VARICELLA ZOSTER VIRUS; VIRUS GENE; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 0035216163     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70193-8     Document Type: Article

References (114)

1. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
2. Clinical experience with famciclovir against hepatitis B virus
3. Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease
4. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing therapy
5. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: Report from the Dionysos study
6. A human cytomegalovirus mutant resistant to the nucleoside using analog 9-([2-hydroxy-1-9{hydroxymethyl}ethoxy]methyl) guanine (BW B759U) induces reduced levels of BW B 759U triphosphate
7. Australia antigen and the biology of hepatitis B
8. Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis
9. Antiviral L-nucleosides specific for hepatitis B virus infection
10. Biology and genetic heterogeneity of hepatitis C virus
11. Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus
12. Recurrence of hepatitis C virus infection after orthotopic liver transplantation: Role of genotypes
13. Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study
14. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance
15. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates
16. A non-codon deletion mutation in the cytomegalovirus UL 97 phosphotransferase gene confers resistance to ganciclovir
17. Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype lb hepatitis C virus
18. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments
19. Persisting long-term benefit of genotypeguided treatment for HIV-infected patients failing HAART. The Viradapt Study: Week 48 follow-up
20. Disseminated herpes zoster in patients with human immunodeficiency virus infection
21. Mechanisms of herpes virus resistance
22. Hepatitis C virus genotypes and quasispecies
23. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis
24. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus in immunocompromised patients
25. Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir
26. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
27. EASL International Consensus Conference on Hepatitis C
28. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center
29. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus lb
30. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C
31. Resistance of human cytomegalovirus to antiviral drugs
32. Antiviral susceptibilities and analysis of UL 97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients
33. Hepatitis B e antigen seroconversion: Effects of lamivudine alone or in combination with interferon alpha
34. "The end of innocence" revisited: Resistance of herpesviruses to antiviral drugs
35. Acyclovir-resistant varicella-zoster virus: Phenotypic and genetic characterization
36. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: A potential mechanism of interferon resistance
37. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients
38. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the amplicor HCV test
39. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C
40. Future directions in the treatment of patients with chronic hepatitis C virus infection
41. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure
42. Why and how to treat chronic hepatitis C
43. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
44. Sexual transmission of anHIV-1 variant resistant to multiple reverse- transcriptase and protease inhibitors
45. Antiretroviral drug resistance testing in adult HIV1 infection: Recommendations of an international AIDS society-USA panel
46. Management of hepatitis C: Current and future perspectives
47. A net + 1 frameshift permits synthesis of thymidine kinase from a drug-resistant herpes simplex virus mutant
48. Transmission of human immunodefidency virus type 1-resistant to nevirapine and zidovudine
49. The response of the hepatitis C and hepatitis G viruses to treatment with recombinant interferon alfa-2b
50. Chronic varicella-zoster infection in acquired immunodeficiency syndrome
51. Oral treatment for hepatitis B gets approval in the United States
52. Clinical monitoring of HIV-1 infection in the era of antiretroviral resistance testing
53. Defined large-scale alteration of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids
54. The use of flow cytometry to detect antiviral resistance in human cytomegalovirus
55. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients
56. Antiviral resistance: Mechanisms, clinical significance, and future implications
57. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy
58. A one-year trial of lamivudine for chronic hepatitis B
59. A one-year trial of lamivudine for chronic hepatitis B
60. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates
61. Long-term therapy of chronic hepatitis B with lamivudine
62. Role of genotypic analysis of the thymidine kinase gene of herpes simplex virus for determination of neurovirulence and resistance to acyclovir
63. Hepatitis B virus infection
64. Clinical treatment of viral hepatitis
65. Chronic hepatitis B virus infection: Treatment strategies for the next millennium
66. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
67. Novel mutation in the CMV UL 97 associated with resistance to ganciclovir therapy
68. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir
69. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B
70. Typing hepatitis B virus by homology in nucleotide sequence: Comparison of surface antigen subtypes
71. Susceptibility of lamivudine resistant hepatitis B virus to other antivirals: Adefovir and lobucavir
72. Continuous varicella-zoster virus infection associated with acyclovir resistance in a child with AIDS
73. Hepatitis C virus resistance to antiviral therapy
74. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy
75. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
76. Predisolone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis
77. Primary HIV-1 resistance: A new phase in the epidemic?
78. A simplified assay for screening of drug resistance of cell-associated cytomegalovirus strains
79. Differential effect of interferon on hepatitis C virus lb quasispecies in the nonstructural protein 5A gene
80. Predictors of response to interferon therapy
81. Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir
82. Conquering hepatitis C, step by step
83. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
84. Therapy for genital herpes in immunocompromised patients: A national survey
85. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B
86. Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS Clinical Trials Group 333
87. The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B
88. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients
89. Viral heterogeneity of the hepatitis C virus virus
90. A proposed system for the nomenclature of hepatitis C viral genotypes
91. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region
92. Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance
93. Current pharmacological approaches to the therapy of varicella-zoster virus infections: A guide to treatment
94. Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-lb in infection
95. Ganciclovir-resistant cytomegalovirus and clinical isolates: Mode of resistance to ganciclovir
96. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy
97. Line probe assay for rapid detection of drugselected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene
98. Second-generation line probe assay for hepatitis C virus genotying
99. Screening with a shell vial assay for antiviral activity against cytomegalovirus
100. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation
101. Antiviral chemotherapy for the treatment of hepatitis B virus infections
102. Pegylated interferon alfa-2b (PEG-Intron) monotherapy is superior to interferon alfa-2b (Intron-A) for the treatment of chronic hepatitis C
103. A line probe assay for hepatitis B virus genotypes
104. Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS
105. Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS
106. Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene
107. Antiviral therapy of herpes simplex and varicella-zoster virus infections
108. Mutations in hepatitis B virus DNA polymerases which contain mutations arising during famciclovir treatment remain sensitive to adefovir
109. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy
110. Clinical significance of hepatitis C virus genotypes
111. Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy
112. Peginterferon alfa-2a in patients with chronic hepatitis C
113. Drug therapy for chronic hepatitis B: Antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy